DAVAO CITY — To accommodate at least 1,000 residents daily, the City Government of Davao opened on Tuesday, June 2, its biggest vaccination site at the Azuela Cove in Lanang that can cater to up to 1,000 recipients per day.
The city government, in a press statement quoted City Health Office (CHO) Acting Head Dr. Ashley Lopez saying, “This is actually so far the biggest vaccination site nga atong na-establish (that we have established) here in Davao City, which could cater up to 1,000 recipients or 1,000 vaccines per day”.
The same statement said, Lopez is hoping that there will be no more delays in the vaccine allocation from the national government because the city has utilized the Astra Zeneca.
“Nahurot na ang Pfizer. Natagaan ta additional vaccines from DOH 11, katong Sinovac pero pahurutay na pud ning Sinovac. Hopefully dili ma-stop o ma-interrupt ang supply nato so that makapadayon ta og ma-maximize atong pagpabakuna (We’re hoping that the vaccine allocation from the national government won’t be delayed since we have run out of Pfizer vaccines. DOH 11 gave us additional Sinovac vaccines, which are also running out as of this time. We hope our vaccine supply won’t be stopped nor interrupted).”
Lopez said the city recently received 6,000 doses of Sinovac vaccines, which are being used in a few vaccination hubs.
But he assured that the National COVID-19 Task Force promised to send more Sinovac and AstraZeneca vaccines and some 200,000 Pfizer vaccines that are tentatively scheduled to arrive on June 6 and 7.
He also confirmed that some of the 21 vaccination sites are really not continuously operational for an entire month.
“We need to disinfect. Kinahanglan nato sila ipahulay. Dili na pwede na whole month nga operation kay
dapat naa silay interval at least one week for disinfection apil napud break sa atong staff (They need to also rest. We can’t operate a vaccination site for the entire month, there needs to be at least one week for disinfection and break of the staff),” Lopez added.
The city is currently catering to those under the A3 priority group or persons with comorbidities. Belonging in this group are those with chronic respiratory disease and infection (asthma and respiratory allergies, chronic obstructive pulmonary disease, interstitial lung diseases, cystic fibrosis, or pulmonary hypertension, pulmonary tuberculosis, chronic bronchitis, histoplasmosis, bronchiectasis); cardiovascular disease (hypertension coronary heart diseases, cardiomyopathies, peripheral artery disease, aortic diseases, rheumatic heart disease, congenital heart disease); chronic kidney disease; cerebrovascular diseases (stroke and transient ischemic attack); cancer of malignancy;
Diabetes mellitus type 1 and 2; obesity; neurologic diseases (dementia, Alzheimer’s Disease, Parkinson’s Disease, epilepsy and seizures, Bell’s palsy, Guillain-Barre Syndrome, or acute spinal cord injury); chronic liver disease (hepatitis cirrhosis, non-alcoholic fatty liver disease);
immunodeficiency states (genetic immunodeficiencies, secondary or acquired immunodeficiencies (i.e. prolonged use of corticosteroids; HIV infection, solid organ or blood transplant patients), and other diseases such as sickle cell disease, thalassemia, or down syndrome.-with CIO report
